drugset / Trial / NCT00179465
Treating Schizophrenia by Correcting Abnormal Brain Development
Phase 3
Active not recruiting
36 enrolled
Beth Israel Deaconess Medical Center
Dartmouth-Hitchcock Medical Center · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
Timeline
- Start
- 2003-11
- Primary completion
- 2026-09
- Completion
- 2026-09
Publications
- Background Woo TU, Crowell AL. Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res. 2005 Mar 1;73(2-3):193-207. doi: 10.1016/j.schres.2004.07.022.
- Background Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5341-6. doi: 10.1073/pnas.95.9.5341.
- Background Woo TU, Spencer K, McCarley RW. Gamma oscillation deficits and the onset and early progression of schizophrenia. Harv Rev Psychiatry. 2010 May-Jun;18(3):173-89. doi: 10.3109/10673221003747609.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tiagabine | Small molecule | 36 mg | — |